DeepTek.ai has achieved FDA clearance for its pioneering Chest X-ray AI solution, the CXR Analyzer, marking a significant milestone. This advanced technology employs deep learning algorithms to automatically detect and categorize abnormalities in chest X-rays, offering comprehensive coverage of lung, pleural, and cardiac pathologies, and more. With compatibility across various X-ray machines, it addresses the critical need for precise interpretation in a world with 1.5 billion annual chest X-rays. DeepTek’s AI reduces radiologists’ workload by 30-50%, making it a game-changer in healthcare. Their proven impact includes transforming healthcare in India, serving over 500 facilities, and Singapore’s National Radiology AI platform deployment.
In a significant development, DeepTek.ai, a prominent player in the field of medical imaging AI headquartered in India, proudly announces its successful attainment of clearance from the U.S. Food and Drug Administration (FDA) for its groundbreaking AI solution dedicated to Chest X-rays – the CXR Analyzer. This cutting-edge technology harnesses the power of deep learning algorithms to identify and flag abnormalities present in chest X-ray images. The CXR Analyzer not only detects anomalies but also categorizes and highlights them automatically, providing invaluable assistance to healthcare professionals in making precise interpretations.
What sets DeepTek’s Chest X-ray AI apart from conventional point AI solutions is its comprehensive coverage of the entire chest area. It extends its analytical capabilities to a wide spectrum of pulmonary, pleural, and cardiac pathologies, and even foreign bodies or hardware on the chest. Remarkably versatile, it seamlessly integrates with a variety of X-ray machines, including those found in hospitals, mobile units, portable devices, hand-held units, and ultra-portable systems.
The transformative potential of this AI model lies in its ability to expedite decision-making processes by swiftly detecting and pinpointing suspicious lesions in chest X-rays. Such capabilities are paramount for the accurate diagnosis of conditions like lung infections, cancer, and chronic lung diseases. In a world where annual X-ray examinations number around 3.5 billion, of which 1.5 billion are chest X-rays, the demand for precise and timely interpretation cannot be overstated. The scarcity of radiologists further underscores the critical role of AI in addressing this pressing challenge.
Dr. Amit Kharat, Co-Founder of DeepTek.ai, expresses his enthusiasm, stating, “DeepTek CXR Analyzer v1.0 is a game-changing innovation that substantially reduces the workload of radiologists by an impressive margin of 30-50%. With FDA clearance in hand, we are not only gaining access to the extensive U.S. healthcare market but also impacting lives on a global scale. By swiftly identifying lung abnormalities and providing precise mapping, we are unlocking a world of possibilities for improved healthcare outcomes across various medical specialties.”
DeepTek’s AI solutions have already been instrumental in transforming healthcare in India and the Asia-Pacific region by enhancing access to quality care at a lower cost. Currently, over 500 hospitals and imaging centers are leveraging DeepTek’s AI solutions, positively affecting the lives of approximately 100,000 individuals each month. Furthermore, DeepTek’s Chest X-Ray Analyzer has facilitated tuberculosis screening for more than half a million individuals. In Singapore, DeepTek’s FDA-approved platform, Augmento, serves as the National Radiology AI platform, significantly enhancing productivity and the quality of care in all public hospitals.
With its operational base in Pune, DeepTek boasts a team of around 200 dedicated professionals and has formed strategic partnerships with industry giants such as TATA Capital, NTT DATA Japan, and Shimadzu Asia Pacific.
